Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Kadota, Tsukasa ^a,b   Matsui, Hirotoshi ^a   Hirose, Takashi ^a   Suzuki, Junko ^a   Saito, Minako ^a   Akaba, Tomohiro ^a   Kobayashi, Kouichi ^a   Akashi, Shunsuke ^a   Kawashima, Masahiro ^a   Tamura, Atsuhisa ^a   Nagai, Hideaki ^a   Akagawa, Shinobu ^a   Kobayashi, Nobuyuki ^a   Ohta, Ken ^a  

^a TOKYO NATIONAL HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug resistance; Drug therapy; Macrolides; Mycobacterium avium complex

Indexed keywords

AMIKACIN; AZITHROMYCIN; C REACTIVE PROTEIN; CLARITHROMYCIN; ETHAMBUTOL; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; RIFAMPICIN; SERUM ALBUMIN; SITAFLOXACIN; STREPTOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIUM ISOLATE; CLARITHROMYCIN RESISTANT MYCOBACTERIUM AVIUM COMPLEX; CLINICAL ARTICLE; FEMALE; HUMAN; LUNG DISEASE; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM COMPLEX; NONHUMAN; RISK FACTOR; SPUTUM ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ISOLATION AND PURIFICATION; LUNG DISEASES; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDY; SPUTUM; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; C-REACTIVE PROTEIN; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LUNG DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SPUTUM; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84955278803     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1384-7     Document Type: Article

References (28)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416.
2. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970-6.
3. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182:977-82.
4. Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994;149:1335-41.
5. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866-72.
6. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928-34.
7. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2012;11:CD002203.
8. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829-32.
9. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. COPD Clinical Research Network: azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689-98.
10. Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139-47.
11. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251-9.
12. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309:1260-7.
13. American Thoracic Society and the Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376.
14. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes. 2nd ed. 2011. Clinical and Laboratory Standards Institute; M24-T2.
15. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186:559-65.
16. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother. 2012;18:436-43.
17. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007;101:130-8.
18. The Committee for Classification of Tuberculosis in the Japanese Society for Tuberculosis. The criteria of chest roentgenogram classification of pulmonary tuberculosis established by the Japanese Society for Tuberculosis. Kekkaku. 1959;34:885-8.
19. Jeon K, Kwon OJ, Lee NY, Kim B-J, Kook Y-H, Lee S-H, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180:896-902.
20. Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis. 2012;25:218-27.
21. Shiraishi Y, Katsuragi N, Kita H, Hyogotani A, Saito MH, Shimoda K. Adjuvant surgical treatment of nontuberculous mycobacterial lung disease. Ann Thorac Surg. 2013;96:287-91.
22. Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg. 2008;85:1887-92. discussion 1892-3.
23. Fujita M, Kajiki A, Tao Y, Miyazaki M, Ouchi H, Harada E, et al. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. J Infect Chemother. 2012;18:146-51.
24. Koh W-J, Hong G, Kim S-Y, Jeong B-H, Park HY, Jeon K, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57:2281-5.
25. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis. 1996;22:S3-14.
26. Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multi-drug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995;171:747-50.
27. Wallace Jr RJ, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153:1766-72.
28. Shafran SD, Deschênes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. N Engl J Med. 1994;330:438-9.